rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NKTR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Nektar at UBS Global Biopharma Conference 2026: durability takes center stage
      Nov 17Investing.comNKTRUBS
      NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down

      Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.

      Nov 13Yahoo FinanceNKTR
      Nektar Therapeutics reports $952.9 million in cash and investments as of Q3 By Investing.com
      Nov 13Investing.comNKTR
      What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
      Nov 13Yahoo FinanceNKTR
      Earnings call transcript: Nektar Therapeutics posts Q3 2026 EPS beat as shares fall
      Nov 12Investing.comNKTR
      Nektar earnings beat by $0.45, revenue fell short of estimates
      Nov 12Investing.comNKTR
      Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates
      Nov 12Yahoo FinanceNKTR
      Nektar: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceNKTR
      Nektar earnings in focus as investors await clinical milestones By Investing.com
      Nov 12Investing.comNKTR
      Nektar Therapeutics to Participate in Two Investor Conferences in November
      Nov 11MorningstarNKTR
      How New Eczema Drug Trials Will Impact Nektar Therapeutics (NKTR) Investors
      Nov 7Yahoo FinanceNKTR
      Is Nektar Therapeutics (NKTR) Overvalued After A 407% Three Year Run?
      Nov 6Yahoo FinanceNKTR
      Nektar Therapeutics: Focus Returns To The Strengths Of The Company (NASDAQ:NKTR)
      Oct 30Seeking AlphaNKTR
      Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
      Oct 27Yahoo FinanceNKTR
      Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Inducement Plan, as amended.

      Oct 23Yahoo FinanceNKTR
      Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
      Oct 15Yahoo FinanceNKTR
      Exclusive BAC Article: Nektar Therapeutics; 52-Week Off-Treatment Data Rezpeg AD Q1 2027, Initiation Of Ph3 AA Study Early 2027, Novel MOA, And Catalysts (NASDAQ:NKTR)

      I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Nektar Therapeutics (NKTR).

      Oct 13Seeking AlphaNKTR
      Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC)

      Tipranks Press Release.

      Oct 13The Globe and MailHSICNKTR
      Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
      Oct 12Seeking AlphaNKTRPTGXSTTK
      Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case
      Oct 12Yahoo FinanceNKTR
      Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target
      Oct 12Yahoo FinanceNKTR
      UBS initiates Nektar Therapeutics stock at Neutral on catalyst timing
      Oct 12Investing.comNKTRUBS
      Raymond James Initiates Nektar Therapeutics at Market Perform
      Oct 9Yahoo FinanceNKTR
      how InvestingPro spotted Nektar’s 47% decline two months early By Investing.com
      Oct 9Investing.comNKTR
      Raymond James initiates Nektar stock coverage with Market Perform
      Oct 8Investing.comNKTR
      Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

      Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here. In Q3 2026, Cedar Grove Capital Management’s Multi-Strategy Composite returned -12.7%, trailing the Russell 2000 (-7.2%), Russell Microcap (-7.4%), and S&P 500 (+2.4%). Since its January 14, 2026, inception, the composite has returned -26.2%, compared […]

      Oct 7Yahoo FinanceNKTRLLY
      Nektar Therapeutics stock analysis: oversold technicals meet binary clinical risk
      Oct 5Investing.comNKTR
      Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow (NASDAQ:NKTR) 2026-10-03

      2026-10-03. The following slide deck was published by Nektar Therapeutics in conjunction with this event.

      Oct 3Seeking AlphaNKTR
      Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More (NKTR)

      Nektar Therapeutics downgraded to Hold: REZPEG shows strong efficacy but safety risks. Learn what this means for AA/AD trials and NKTR investors.

      Oct 2Seeking AlphaNKTR
      H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data
      Oct 2Investing.comNKTR
      This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
      Oct 1Barron'sNKTR
      Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
      Oct 1Yahoo FinanceNKTR
      This Biotech Just Got Slammed On Its Promising Alopecia Data

      Nektar stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.

      Oct 1Investor's Business DailyNKTR
      /UPDATE — Nektar Therapeutics/
      Oct 1MorningstarNKTR
      /UPDATE -- Nektar Therapeutics/

      Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral presentation sessions.

      Oct 1Yahoo FinanceNKTR
      Nektar presents long-term data on alopecia areata drug candidate
      Oct 1Investing.comNKTR
      Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Nektar Therapeutics (NKTR) and Stryker (SYK)

      Detailed price information for Docgo Inc. (DCGO-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailDCGONKTR
      NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
      Oct 1Yahoo FinanceNKTR
      Nektar Therapeutics Says Rezpegaldesleukin in Atopic Dermatitis Showed Improvements as Early as Week 2

      Nektar Therapeutics (NKTR) said Wednesday that rezpegaldesleukin-associated molecular changes were d

      Sep 30Yahoo FinanceNKTR
      Nektar presents biomarker data on atopic dermatitis drug
      Sep 30Investing.comNKTR
      How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors

      Nektar Therapeutics recently announced that data from its Phase 2b rezpegaldesleukin trials in atopic dermatitis and alopecia areata were presented in three oral sessions at the 2026 EADV Congress in Vienna, including new 6‑month off‑treatment results in severe alopecia areata and maintenance data in atopic dermatitis. The inclusion of late‑breaking multi‑omic findings from the REZOLVE‑AD biomarker sub‑study adds an unusual level of mechanistic insight that could influence how investors...

      Sep 30Yahoo FinanceNKTR
      What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case?

      Nektar Therapeutics (NasdaqCM:NKTR) plans three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology Congress 2026. The talks will share 6‑month off‑treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Multi‑omic biomarker findings from atopic dermatitis patients on rezpegaldesleukin are also scheduled for presentation at EADV 2026. The new rezpegaldesleukin durability and biomarker readouts come in addition to a...

      Sep 30Yahoo FinanceNKTR
      Nektar to present alopecia areata drug data at EADV congress
      Sep 28Investing.comNKTR
      Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?
      Sep 28Yahoo FinanceNKTR
      Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
      Sep 28Yahoo FinanceNKTR
      A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved

      Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.

      Sep 26Yahoo FinanceNKTRLLY
      Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says
      Sep 25ReutersNKTRLLY
      Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

      All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema

      Sep 25Yahoo FinanceAKAMNKTRSCHLLLY
      Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal

      (Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK

      Sep 25Yahoo FinanceNKTRLLY
      Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds

      A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in August 2023, stemmed from a previous licensing agreement between the two companies for the development and commercialization of the drug rezpegaldesleukin. Jury Finds Breach of Covenant The trial in the U.S

      Sep 25Yahoo FinanceNKTR

      This is the newest page. Registered accounts read further back.